A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

BACKGROUND: Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Kerry Lynn, Bedard, Philippe L., Lee, Se-Hoon, Lin, Chia-Chi, Tabernero, Josep, Alsina, Maria, Cohen, Ezra, Baselga, José, Blumenschein, George, Graham, Donna M., Garrido-Laguna, Ignacio, Juric, Dejan, Sharma, Sunil, Salgia, Ravi, Seroutou, Abdelkader, Tian, Xianbin, Fernandez, Rose, Morozov, Alex, Sheng, Qing, Ramkumar, Thiruvamoor, Zubel, Angela, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596462/
https://www.ncbi.nlm.nih.gov/pubmed/28899363
http://dx.doi.org/10.1186/s12885-017-3641-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596462/
https://www.ncbi.nlm.nih.gov/pubmed/28899363
http://dx.doi.org/10.1186/s12885-017-3641-6

Ejemplares similares